ClinicalTrials.gg
CompletedNCT01136382CHASE 1Updated Aug 1, 2014Results posted

A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo

A Phase 2 interventional study of budesonide and placebo in Asthma, sponsored by AstraZeneca. Completed at 87 sites in 7 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2014-08-01.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
36th of 108
304 · median 124
Started
2010
with 5 others
Phase 2
5 of 110
none open now
Registered
66th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 36th largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2010, is one of 5 in phase 2, and was the 66th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

This purpose of the study is to investigate if budesonide pMDI 160 �g twice a day during 6 weeks is effective and safe in treating asthmatic children aged 6 to \<12 years

Read the detailed description

Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 �g bid with placebo: a 6-week efficacy and safety study in children aged 6 to \<12 years with asthma

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma, children, budesonide pMDI
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a documented clinical diagnosis of asthma for at least 6 months prior to Visit 2 that has required daily inhaled in the low dose range OR LTRA as monotherapy for at least 30 days prior to Visit 2.
  • Has a morning clinic pre-bronchodilator measured at least 6 hours after the last dose of inhaled short acting beta agonist of greater than or equal to 70% and less than or equal to 95% of predicted normal
  • Demonstrated reversibility of FEV1 of ≥12% from pre short acting beta agonist level within 15 to 30 minutes after administration of a standard dose of short acting beta agonist OR has a documented reversibility of ≥ 12 % within 12 months prior to Visit 2.

Exclusion criteria

Exclusion Criteria:

  • Has been hospitalized at least once or required emergency treatment (was seen in the emergency room or had an urgent care visit) more than once for an asthma-related condition during the 6 months prior to Visit 2
  • Has required treatment with systemic (eg, oral, parenteral, or rectal) for any reason within the 12 weeks prior to Visit 2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    1

    Budesonide pMDI 160 ug bid (80 ug x 2 inhalations bid)

    Drug: budesonide

  • Placebo comparator
    2

    Placebo pMDI 2 inhalations bid

    Drug: placebo

Interventions

  • pMDI, inhalation, bid, 6 weeks

  • Drugplacebo

    pMDI, inhalation, bid, 6 weeks

06

What researchers measure

Primary outcomes

  1. Change in Morning Peak Expiratory Flow (PEF) From Baseline to the Treatment Period Average

    The peak expiratory flow rate is the maximal rate that a person can exhale during a short maximal expiratory effort after a full inspiration. Baseline was calculated using the mean of the data recorded during the last 7 days of the run-in period, and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.

    Time frame: Baseline to 6 weeks

Secondary outcomes

  1. Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Treatment Period Average

    FEV1 is the volume exhaled during the first second of a forced expiratory maneuver started from the level of total lung capacity. Baseline was defined as the pre-dose assessment value measured at randomization (Visit 3), and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.

    Time frame: Baseline to 6 weeks

  2. Change in Evening PEF From Baseline to the Treatment Period Average

    The peak expiratory flow rate is the maximal rate that a person can exhale during a short maximal expiratory effort after a full inspiration. Baseline was calculated using the mean of the data recorded during the last 7 days of the run-in period, and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.

    Time frame: Baseline to 6 weeks

  3. Change in Forced Vital Capacity (FVC) From Baseline to Treatment Period Average

    FVC is the total volume of air expired after a full inspiration. Baseline was defined as the pre-dose assessment value measured at randomization (Visit 3), and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.

    Time frame: Baseline to 6 weeks

  4. Change in Forced Mid-expiratory Flow Between 25% and 75% of the FVC (FEF25-75) From Baseline to Treatment Period Average

    FEF25-75 is the average rate of airflow during the midportion of the forced vital capacity. Baseline was defined as the pre-dose assessment value measured at randomization (Visit 3), and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.

    Time frame: Baseline to 6 weeks

  5. Change in Total Daily and Daytime Asthma Symptom Scores From Baseline to Treatment Period Average

    Patients, with the help of their caregiver, were required to rate and document their asthma symptoms twice daily as an overall symptom score for the time period since their previous recording. The following rating scales were used: 0 = None; no symptoms of asthma; 1 = Mild symptoms; awareness of asthma symptoms and/or signs that are easily tolerated; 2 = Moderate symptoms, asthma symptoms with some discomfort, causing some interference with daily activities or sleep; 3 = Severe symptoms; incapacitating asthma symptoms and/or signs, with inability to perform daily activities or to sleep.

    Time frame: Baseline to 6 weeks

  6. Change in Nighttime Asthma Symptom Score From Baseline to Treatment Period Average

    Patients, with the help of their caregiver, were required to rate and document their asthma symptoms twice daily as an overall symptom score for the time period since their previous recording. The following rating scales were used: 0 = None; no symptoms of asthma; 1 = Mild symptoms; awareness of asthma symptoms and/or signs that are easily tolerated; 2 = Moderate symptoms, asthma symptoms with some discomfort, causing some interference with daily activities or sleep; 3 = Severe symptoms; incapacitating asthma symptoms and/or signs, with inability to perform daily activities or to sleep.

    Time frame: Baseline to 6 weeks

  7. Change in Nighttime Awakenings and Nighttime Awakenings With Reliever Medication Use From Baseline to Treatment Period Average

    Patients, with the help of their caregiver, were asked to respond to a standard question each morning as they completed their eDiary. The question to be answered was, "Did your asthma cause you to wake-up last night?" If yes, patients were asked, "Did you need to use your reliever medication (albuterol/salbutamol inhaler) before you went back to sleep?" Baseline is defined as the percentage of days where patient experienced nighttime awakenings out of all available days where data was collected during the last 7 days of the run-in period.

    Time frame: Baseline to 6 weeks

  8. Change in Total Daily and Daytime Reliever Medication Use From Baseline to Treatment Period Average

    The patient, with the help of their caregiver, recorded the number of inhalations of reliever medication used, for relief of asthma symptoms, twice daily in the eDiary. Patients were asked to respond to a standard question twice daily (morning and evening). The question to be answered was, "How many albuterol/salbutamol inhalations since last diary entry?"

    Time frame: Baseline to 6 weeks

  9. Change in Nighttime Reliever Medication Use From Baseline to Treatment Period Average

    The patient, with the help of their caregiver, recorded the number of inhalations of reliever medication used, for relief of asthma symptoms, twice daily in the eDiary. Patients were asked to respond to a standard question twice daily (morning and evening). The question to be answered was, "How many albuterol/salbutamol inhalations since last diary entry?"

    Time frame: Baseline to 6 weeks

  10. Number of Withdrawals Due to Pre-defined Asthma Events

    Patients were considered to have experienced a "pre-defined asthma event" if any of the following conditions were met during the study: 1. At each visit or follow-up visit, a decrease in morning pre-dose FEV1 \>=20% from the Visit 3 (randomization visit) morning pre-dose FEV1 or a decrease to \<65% of predicted normal value; 2. The use of \>=8 actuations of albuterol/salbutamol per day on 3 or more days within any period of 7 consecutive days following randomization; 3. A decrease in morning PEF \>=20% from baseline on 3 or more days within any period of 7 consecutive days after randomization; 4. Two or more nights with an awakening due to asthma, which required the use of reliever medication within any period of 7 consecutive days after randomization; 5. A clinical exacerbation requiring emergency treatment, hospitalization, or use of an asthma medication not allowed by the study protocol.

    Time frame: Baseline to 6 weeks

07

Results

Posted Jul 21, 2014

Participant flow

This multicenter study was conducted in Bulgaria, Hungary, Latvia, Poland, Slovakia, South Africa, and the United States between 07 August 2011 and 05 April 2013.

Participant flow — Overall Study
MilestonePlaceboBudesonide
Started152152
Completed92121
Not completed6031
Withdrew: Other83
Withdrew: Study-specific withdrawal criteria4825
Withdrew: Severe non-compliance to protocol02
Withdrew: Withdrawal by subject41

Outcome measures

PrimaryChange in Morning Peak Expiratory Flow (PEF) From Baseline to the Treatment Period Average

The peak expiratory flow rate is the maximal rate that a person can exhale during a short maximal expiratory effort after a full inspiration. Baseline was calculated using the mean of the data recorded during the last 7 days of the run-in period, and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · liters/minute
Change in Morning Peak Expiratory Flow (PEF) From Baseline to the Treatment Period Average
liters/minutePlaceboBudesonide
Change in Morning Peak Expiratory Flow (PEF) From Baseline to the Treatment Period Average4.1 ± 3.1917.8 ± 3.24
Statistical analysis
  • Placebo vs Budesonide · ANCOVA · p = <0.0001 (To address multiplicity, a step-down procedure was used. If the treatment difference for the primary variable, morning PEF, was statistically significant (p\<0.05), then the key secondary variable, FEV1, was tested at the 0.05 level of significance.) · Ls mean difference: 13.6 · 95% CI 7.5 to 19.7
SecondaryChange in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Treatment Period Average

FEV1 is the volume exhaled during the first second of a forced expiratory maneuver started from the level of total lung capacity. Baseline was defined as the pre-dose assessment value measured at randomization (Visit 3), and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · liters
Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Treatment Period Average
litersPlaceboBudesonide
Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Treatment Period Average0.00 ± 0.0230.06 ± 0.023
Statistical analysis
  • Placebo vs Budesonide · ANCOVA · p = 0.0047 (To address multiplicity, a step-down procedure was used. If the treatment difference for the primary variable, morning PEF, was statistically significant (p\<0.05), then the key secondary variable, FEV1, was tested at the 0.05 level of significance.) · Ls mean difference: 0.06 · 95% CI 0.02 to 0.11
SecondaryChange in Evening PEF From Baseline to the Treatment Period Average

The peak expiratory flow rate is the maximal rate that a person can exhale during a short maximal expiratory effort after a full inspiration. Baseline was calculated using the mean of the data recorded during the last 7 days of the run-in period, and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · liters/minute
Change in Evening PEF From Baseline to the Treatment Period Average
liters/minutePlaceboBudesonide
Change in Evening PEF From Baseline to the Treatment Period Average4.0 ± 3.0814.7 ± 3.13
Statistical analysis
  • Placebo vs Budesonide · ANCOVA · p = 0.0004 · Ls mean difference: 10.8 · 95% CI 4.9 to 16.7
SecondaryChange in Forced Vital Capacity (FVC) From Baseline to Treatment Period Average

FVC is the total volume of air expired after a full inspiration. Baseline was defined as the pre-dose assessment value measured at randomization (Visit 3), and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · liters
Change in Forced Vital Capacity (FVC) From Baseline to Treatment Period Average
litersPlaceboBudesonide
Change in Forced Vital Capacity (FVC) From Baseline to Treatment Period Average0.00 ± 0.0210.04 ± 0.021
Statistical analysis
  • Placebo vs Budesonide · ANCOVA · p = 0.0673 · Ls mean difference: 0.04 · 95% CI 0.00 to 0.08
SecondaryChange in Forced Mid-expiratory Flow Between 25% and 75% of the FVC (FEF25-75) From Baseline to Treatment Period Average

FEF25-75 is the average rate of airflow during the midportion of the forced vital capacity. Baseline was defined as the pre-dose assessment value measured at randomization (Visit 3), and the treatment period average was calculated as the mean of all available data recorded during the entire treatment period.

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · liters/second
Change in Forced Mid-expiratory Flow Between 25% and 75% of the FVC (FEF25-75) From Baseline to Treatment Period Average
liters/secondPlaceboBudesonide
Change in Forced Mid-expiratory Flow Between 25% and 75% of the FVC (FEF25-75) From Baseline to Treatment Period Average0.01 ± 0.0450.11 ± 0.045
Statistical analysis
  • Placebo vs Budesonide · ANCOVA · p = 0.0216 · Ls mean difference: 0.10 · 95% CI 0.01 to 0.19
SecondaryChange in Total Daily and Daytime Asthma Symptom Scores From Baseline to Treatment Period Average

Patients, with the help of their caregiver, were required to rate and document their asthma symptoms twice daily as an overall symptom score for the time period since their previous recording. The following rating scales were used: 0 = None; no symptoms of asthma; 1 = Mild symptoms; awareness of asthma symptoms and/or signs that are easily tolerated; 2 = Moderate symptoms, asthma symptoms with some discomfort, causing some interference with daily activities or sleep; 3 = Severe symptoms; incapacitating asthma symptoms and/or signs, with inability to perform daily activities or to sleep.

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · units on a scale
Change in Total Daily and Daytime Asthma Symptom Scores From Baseline to Treatment Period Average
units on a scalePlaceboBudesonide
Daytime asthma symptom score-0.2 ± 0.06-0.4 ± 0.06
Total asthma symptom score-0.5 ± 0.11-0.8 ± 0.11
Statistical analysis
  • Placebo vs Budesonide · ANCOVA · p = 0.0004 (Analysis for change in daytime asthma symptom score from baseline to treatment period average.) · Ls mean difference: -0.2 · 95% CI -0.31 to -0.09
  • Placebo vs Budesonide · ANCOVA · p = 0.0015 (Analysis for change in total asthma symptom score from baseline to treatment period average.) · Ls mean difference: -0.3 · 95% CI -0.55 to -0.13
SecondaryChange in Nighttime Asthma Symptom Score From Baseline to Treatment Period Average

Patients, with the help of their caregiver, were required to rate and document their asthma symptoms twice daily as an overall symptom score for the time period since their previous recording. The following rating scales were used: 0 = None; no symptoms of asthma; 1 = Mild symptoms; awareness of asthma symptoms and/or signs that are easily tolerated; 2 = Moderate symptoms, asthma symptoms with some discomfort, causing some interference with daily activities or sleep; 3 = Severe symptoms; incapacitating asthma symptoms and/or signs, with inability to perform daily activities or to sleep.

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · units on a scale
Change in Nighttime Asthma Symptom Score From Baseline to Treatment Period Average
units on a scalePlaceboBudesonide
Change in Nighttime Asthma Symptom Score From Baseline to Treatment Period Average-0.3 ± 0.06-0.4 ± 0.06
Statistical analysis
  • Placebo vs Budesonide · ANCOVA · p = 0.0079 · Ls mean difference: -0.1 · 95% CI -0.26 to -0.04
SecondaryChange in Nighttime Awakenings and Nighttime Awakenings With Reliever Medication Use From Baseline to Treatment Period Average

Patients, with the help of their caregiver, were asked to respond to a standard question each morning as they completed their eDiary. The question to be answered was, "Did your asthma cause you to wake-up last night?" If yes, patients were asked, "Did you need to use your reliever medication (albuterol/salbutamol inhaler) before you went back to sleep?" Baseline is defined as the percentage of days where patient experienced nighttime awakenings out of all available days where data was collected during the last 7 days of the run-in period.

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · percentage of days with awakenings
Change in Nighttime Awakenings and Nighttime Awakenings With Reliever Medication Use From Baseline to Treatment Period Average
percentage of days with awakeningsPlaceboBudesonide
Nighttime awakenings-9.8 ± 1.81-14.5 ± 1.84
Nighttime awakenings with reliever use-6.1 ± 1.17-10.0 ± 1.18
Statistical analysis
  • Placebo vs Budesonide · ANCOVA · p = 0.0095 (Analysis for change in nighttime awakenings from baseline to treatment period average.) · Ls mean difference: -4.7 · 95% CI -8.2 to -1.1
  • Placebo vs Budesonide · ANCOVA · p = 0.0007 (Analysis for change in nighttime awakenings with reliever medication use from baseline to treatment period average.) · Ls mean difference: -3.9 · 95% CI -6.2 to -1.7
SecondaryChange in Total Daily and Daytime Reliever Medication Use From Baseline to Treatment Period Average

The patient, with the help of their caregiver, recorded the number of inhalations of reliever medication used, for relief of asthma symptoms, twice daily in the eDiary. Patients were asked to respond to a standard question twice daily (morning and evening). The question to be answered was, "How many albuterol/salbutamol inhalations since last diary entry?"

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · inhalations per day
Change in Total Daily and Daytime Reliever Medication Use From Baseline to Treatment Period Average
inhalations per dayPlaceboBudesonide
Daytime reliever medication use-0.1 ± 0.07-0.4 ± 0.07
Total reliever medication use-0.3 ± 0.11-0.7 ± 0.11
Statistical analysis
  • Placebo vs Budesonide · ANCOVA · p = 0.0001 (Analysis for change in daytime reliever medication use from baseline to treatment period average.) · Ls mean difference: -0.3 · 95% CI -0.4 to -0.1
  • Placebo vs Budesonide · ANCOVA · p = <0.0001 (Analysis for change in total reliever medication use from baseline to treatment period average.) · Ls mean difference: -0.5 · 95% CI -0.7 to -0.2
SecondaryChange in Nighttime Reliever Medication Use From Baseline to Treatment Period Average

The patient, with the help of their caregiver, recorded the number of inhalations of reliever medication used, for relief of asthma symptoms, twice daily in the eDiary. Patients were asked to respond to a standard question twice daily (morning and evening). The question to be answered was, "How many albuterol/salbutamol inhalations since last diary entry?"

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · inhalations per day
Change in Nighttime Reliever Medication Use From Baseline to Treatment Period Average
inhalations per dayPlaceboBudesonide
Change in Nighttime Reliever Medication Use From Baseline to Treatment Period Average-0.1 ± 0.06-0.4 ± 0.06
Statistical analysis
  • Placebo vs Budesonide · ANCOVA · p = <0.0001 · Ls mean difference: -0.2 · 95% CI -0.3 to -0.1
SecondaryNumber of Withdrawals Due to Pre-defined Asthma Events

Patients were considered to have experienced a "pre-defined asthma event" if any of the following conditions were met during the study: 1. At each visit or follow-up visit, a decrease in morning pre-dose FEV1 \>=20% from the Visit 3 (randomization visit) morning pre-dose FEV1 or a decrease to \<65% of predicted normal value; 2. The use of \>=8 actuations of albuterol/salbutamol per day on 3 or more days within any period of 7 consecutive days following randomization; 3. A decrease in morning PEF \>=20% from baseline on 3 or more days within any period of 7 consecutive days after randomization; 4. Two or more nights with an awakening due to asthma, which required the use of reliever medication within any period of 7 consecutive days after randomization; 5. A clinical exacerbation requiring emergency treatment, hospitalization, or use of an asthma medication not allowed by the study protocol.

Time frame:
Baseline to 6 weeks
Reported as:
Number · participants
Number of Withdrawals Due to Pre-defined Asthma Events
participantsPlaceboBudesonide
Number of Withdrawals Due to Pre-defined Asthma Events5025
Statistical analysis
  • Placebo vs Budesonide · Log Rank · p = 0.0004

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Budesonide pMDI 160mcg b.i.d.—0/152 (0%)27/152 (17.8%)
Placebo pMDI b.i.d.—0/152 (0%)40/152 (26.3%)
Most frequent other events
Most frequent other events
EventBudesonide pMDI 160mcg b.i.d.Placebo pMDI b.i.d.
NASOPHARYNGITISInfections and infestations12/1529/152
ASTHMARespiratory, thoracic and mediastinal disorders1/15211/152
PHARYNGITISInfections and infestations5/1528/152
VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/1528/152
INFLUENZAInfections and infestations4/1524/152
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders3/1524/152

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboBudesonideTotal
Mean9.0 ± 1.629.0 ± 1.639.0 ± 1.62
Age, Customized
Age, Customized(participants)PlaceboBudesonideTotal
6 to <8 years333366
8 to- <12 years119119238
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBudesonideTotal
Female5854112
Male9498192
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboBudesonideTotal
Hispanic or Latino101121
Native Hawaiian/Pacific Islander101
African American7916
Asian (other than Chinese and Japanese)022
Not Applicable128126254
Other6410
Forced expiratory volume in 1 second (FEV1)
Forced expiratory volume in 1 second (FEV1)(liters)PlaceboBudesonideTotal
Mean1.70 ± 0.4161.69 ± 0.3881.70 ± 0.401
08

Study locations

87 sites
  • Research Site
    Scottsdale, Arizona, United States
  • Research Site
    Fresno, California, United States
  • Research Site
    Granada Hills, California, United States
  • Research Site
    Huntington Beach, California, United States
  • Research Site
    Mission Viejo, California, United States
  • Research Site
    Orange, California, United States
  • Research Site
    Palmdal, California, United States
  • Research Site
    Rolling Hills Estate, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    Stockton, California, United States
  • Research Site
    Centennial, Colorado, United States
  • Research Site
    Colorado Springs, Colorado, United States
  • Research Site
    Denver, Colorado, United States
  • Research Site
    Coral Gables, Florida, United States
  • Research Site
    Orange City, Florida, United States
  • Research Site
    Sarasota, Florida, United States
  • Research Site
    Albany, Georgia, United States
  • Research Site
    Gainesville, Georgia, United States
  • Research Site
    Normal, Illinois, United States
  • Research Site
    Overland Park, Kansas, United States
  • Research Site
    Bethesda, Maryland, United States
  • Research Site
    North Dartmouth, Massachusetts, United States
  • Research Site
    Ypsilanti, Michigan, United States
  • Research Site
    Plymouth, Minnesota, United States
  • Research Site
    Columbia, Missouri, United States
  • Research Site
    St Louis, Missouri, United States
  • Research Site
    Boseman, Montana, United States
  • Research Site
    Bellevue, Nebraska, United States
  • Research Site
    Omaha, Nebraska, United States
  • Research Site
    Ocean, New Jersey, United States
  • Research Site
    Skillman, New Jersey, United States
  • Research Site
    Teaneck, New Jersey, United States
  • Research Site
    Rockville Centre, New York, United States
  • Research Site
    High Point, North Carolina, United States
  • Research Site
    Canton, Ohio, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Cleveland, Ohio, United States
  • Research Site
    Sylvania, Ohio, United States
  • Research Site
    Toledo, Ohio, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Gresham, Oregon, United States
  • Research Site
    Lake Oswego, Oregon, United States
  • Research Site
    Medford, Oregon, United States
  • Research Site
    Portland, Oregon, United States
  • Research Site
    Altoona, Pennsylvania, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    Upland, Pennsylvania, United States
  • Research Site
    Charleston, South Carolina, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    El Paso, Texas, United States
  • Research Site
    Fort Worth, Texas, United States
  • Research Site
    Georgetown, Texas, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Waco, Texas, United States
  • Research Site
    Richmond, Virginia, United States
  • Research Site
    Greenfield, Wisconsin, United States
  • Research Site
    West Allis, Wisconsin, United States
  • Research Site
    Plovdiv, Bulgaria
  • Research Site
    Ruse, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Budapest, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Gyor, Hungary
  • Research Site
    Kiskunhalas, Hungary
  • Research Site
    Marcali, Hungary
  • Research Site
    Miskolc, Hungary
  • Research Site
    Nyiregyhaza, Hungary
  • Research Site
    Sopron, Hungary
  • Research Site
    Szeged, Hungary
  • Research Site
    Szigetvar, Hungary
  • Research Site
    Torokbalint, Hungary
  • Research Site
    Zalaegerszeg, Hungary
  • Research Site
    Ogre, Latvia
  • Research Site
    Rezekne, Latvia
  • Research Site
    Riga, Latvia
  • Research Site
    Bialystok, Poland
  • Research Site
    Czestochowa, Poland
  • Research Site
    Karpacz, Poland
  • Research Site
    Lodz, Poland
  • Research Site
    Pabianice, Poland
  • Research Site
    Bratislava, Slovakia
  • Research Site
    Lucenec, Slovakia
  • Research Site
    Krugersdorp, Gauteng, South Africa
  • Research Site
    Durban, Kwa Zulu Natal, South Africa
  • Research Site
    Pietermariztburg, Kwa Zulu Natal, South Africa
  • Research Site
    Claremont, W Cape, South Africa
  • Research Site
    Panorama, W Cape, South Africa
09

References and documents

Publications

  • Meltzer EO, Pearlman DS, Eckerwall G, Uryniak T, DePietro M, Lampl K. Efficacy and safety of budesonide administered by pressurized metered-dose inhaler in children with asthma. Ann Allergy Asthma Immunol. 2015 Dec;115(6):516-22. doi: 10.1016/j.anai.2015.09.007. Epub 2015 Oct 13. PubMed 26460293 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2010
First posted
Jun 3, 2010
Start
Jul 2010
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Results first posted
Jul 21, 2014
Last update
Aug 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01136382
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 3, 2010
Start date
Jul 2010
Primary completion
Apr 2013
Completion
Apr 2013
Results posted
Jul 21, 2014
Last update
Aug 1, 2014

Study contacts

Göran Eckerwall, MD
study director · AZ R&D Mölndal

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion